SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership
Executive Summary
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
You may also be interested in...
M&A Already Underway As Angelini Acquires Arvelle
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
Rising COVID-19 Disruption Of Korea's Global R&D
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Need a specific report? 1000+ reports available
Buy Reports